Sjogren's Responds to Cytokine Treatment, Early Data Show

(MedPage Today) -- Most patients with Sjogren's syndrome treated with low doses of interleukin-2 (IL-2) in a randomized, placebo-controlled trial showed significant improvement, researchers said. After 24 weeks in the 60-person trial, 66.7% of...
Source: MedPage Today Rheumatology - Category: Rheumatology Source Type: news